MGI PHARMA to Present at the UBS 2005 Global Life Sciences Conference
20 Septiembre 2005 - 6:00AM
Business Wire
MGI PHARMA, INC. (Nasdaq:MOGN) today announced that it will present
at the UBS 2005 Global Life Sciences Conference on Tuesday,
September 27, at 1:00 p.m. Eastern Time. Lonnie Moulder, president
and chief executive officer of MGI PHARMA, will give the
presentation, which will be webcast live over the Internet. The
conference will be held at the Grand Hyatt New York in New York
City. -0- *T What: MGI PHARMA's presentation at the UBS 2005 Global
Life Sciences Conference When: Tuesday, September 27, 2005 at 1:00
p.m. Eastern Time How: Live over the Internet - simply log on to
www.mgipharma.com. In addition to the live webcast, the
presentation will be archived on the Company's web site for one
week. *T About MGI PHARMA MGI PHARMA, INC. is an oncology and acute
care focused biopharmaceutical company that acquires, develops and
commercializes proprietary products that address the unmet needs of
patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride)
injection, Kadian(R) (sustained release morphine sulfate) capsules,
Salagen(R) Tablets (pilocarpine hydrochloride) and Hexalen(R)
(altretamine) capsules in the United States. The company directly
markets its products in the U.S. and collaborates with partners to
reach international markets. For more information about MGI PHARMA,
please visit www.mgipharma.com. Important Additional Information
Pursuant to a definitive Agreement and Plan of Merger, dated July
20, 2005 (the "Merger Agreement") by and among MGI PHARMA, Granite
Acquisition, Inc. ("Merger Sub"), a wholly owned subsidiary of MGI
PHARMA, and Guilford Pharmaceuticals, Inc. ("Guilford"), upon the
terms and subject to the conditions set forth in the Merger
Agreement, Merger Sub will be merged with and into Guilford, with
Guilford continuing as the surviving corporation as a wholly-owned
subsidiary of MGI PHARMA (the "Merger"). In connection with the
Merger, MGI PHARMA filed with the SEC a registration statement on
Form S-4 containing a Proxy Statement/Prospectus. Investors are
urged to read the registration statement, the Proxy
Statement/Prospectus and all other relevant documents filed or to
be filed with the SEC because they contain important information
about MGI PHARMA, Guilford and the Merger. The final Proxy
Statement/Prospectus has been mailed to Guilford stockholders.
Guilford stockholders are able to obtain the registration
statement, the Proxy Statement/Prospectus and any other relevant
filed documents for free at the SEC's website (www.sec.gov). These
documents can also be obtained for free from MGI by directing a
request to MGI PHARMA Investor Relations at 952-346-4700.
Participants in Solicitation MGI PHARMA, Guilford, and their
directors and officers may be deemed to be participants in the
solicitation of proxies from Guilford stockholders in respect of
the Merger. Information regarding MGI PHARMA's participants is
available in MGI PHARMA's Annual Report on Form 10-K for the year
ended December 31, 2004 and its proxy statement for its 2005 Annual
Meeting of Stockholders, which are filed with the SEC. Information
regarding Guilford's participants is available in Guilford's Annual
Report on Form 10-K for the year ended December 31, 2004 and the
proxy statement for its 2005 Annual Meeting of Stockholders, which
are filed with the SEC. Additional information regarding interests
of such participants will be included in the registration statement
containing the Proxy Statement/Prospectus that has been filed with
the SEC. This news release contains certain "forward-looking"
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as "believes," "expects," "anticipates," "intends,"
"will," "may," "should," or similar expressions. These
forward-looking statements are not guarantees of MGI PHARMA's
future performance and involve a number of risks and uncertainties
that may cause actual results to differ materially from the results
discussed in these statements. Factors that might cause the
Company's results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to, the ability of MGI PHARMA's product candidates to be
proven safe and effective in humans, to receive marketing
authorization from regulatory authorities, and to ultimately
compete successfully with other therapies; continued sales of MGI
PHARMA's marketed products; development or acquisition of
additional products; reliance on contract manufacturing; changes in
strategic alliances; continued access to capital; and other risks
and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission including its
most recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no
duty to update any of these forward-looking statements to conform
them to actual results.
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Mgi Pharma (MM) (NASDAQ): 0 recent articles
Más de MGI PHARMA, INC. Artículos de Noticias